Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE) (I-CARE)

September 1, 2021 updated by: Richard Holden, Indiana University
The specific aims of this study are 1) to test the trial and intervention feasibility of Brain Care Notes (BCN) app, 2) To estimate the effect size of BCN on reducing informal caregiver burden at 6 months, and 3) To estimate the effect size of BCN on reducing patient behavioral and psychological symptoms of dementia (BPSD) at 6 months. Subjects will be recruited from the Aging Brain Care (ABC) program of Eskenazi Health and Indiana University Health located in central Indiana.

Study Overview

Status

Completed

Detailed Description

Informal caregivers of patients with Alzheimer's disease and related dementia (ADRD) manage a complex spectrum of patient behavioral and psychological symptoms of dementia (BPSD). BPSD are major contributing factors to caregivers' burden and adverse health outcomes, leading to an increase of unplanned hospitalizations and a decrease in quality of life. The National Alzheimer's Project Act recognizes the need for interventions that "enable family caregivers to continue to provide care while maintaining their own health and well-being." Furthermore, recommendations from 2015 and 2018 Alzheimer's Disease Research Summits include the application of technology to improve caregiving research and ADRD care

This pilot randomized controlled trial, will test the feasibility and estimate the effect size of integrating mobile health technology BrainCare Notes (BCN) into an existing, fully operational, and self-sustaining clinical program (Aging Brain Care; ABC) and IU Health primary care physician clinics (IUHP). BCN is a mobile application (app) for informal caregivers of patients with Alzheimer's Disease and related dementia (ADRD). The BCN app delivers 24/7 psychoeducation and caregiver support, assessment of informal caregiver status and patients' behavioral and psychological symptoms of dementia (BPSD), and engagement tools for self-management and communication. Over a 15 month accrual period, we propose to enroll from the ABC clinical program and IUHP 60 dyads consisting of an adult patient with ADRD and one (primary) informal caregiver. The intervention will continue for 6 months and final assessments will be completed at 6 months. Feasibility data will be collected throughout the study and assessed at the end of the study by computing: (a) recruitment rate; (b) data completion; (c) BCN usability; (d) BCN acceptance; and (e) BCN use. Caregiver burden and patient BPSD will be collected at baseline, 3, and 6 months and evaluated for changes from baseline to 6 months in each group. Means, standard deviations, and confidence intervals will be computed to test feasibility hypotheses. Mixed linear models will be used to test hypotheses comparing the two conditions at 6 months.

Study Type

Interventional

Enrollment (Actual)

61

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • IU Health
      • Indianapolis, Indiana, United States, 46202
        • Eskenazi Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient has received a diagnosis of possible or probable Alzheimer's disease and Related Dementia from a physician in the ABC Clinical Program;
  • Caregiver is at least 18 years of age and does not have a visual impairment significant enough to interfere with his/her ability to use BCN;
  • Both patient and caregiver are community-dwelling in central Indiana; and
  • Both patient and caregiver are willing to participate in the ABC Clinical Program (including receiving home visits).

Exclusion Criteria:

  • Either the patient or his/her informal caregiver does not have the ability to communicate in English.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ABC Clinical Program Only and Usual Care
Patients and informal caregivers randomized to the comparison group will receive care provided by the ABC Clinical Program and IUHP. The ABC Clinical Program is the standard of ADRD care at Eskenazi Health and Primary Care Visits at Indiana University Health is the usual care.

The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.

The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary.

Other Names:
  • IUHP Usual Care
Experimental: BCN Mobile App Plus ABC and BCN Mobile app only
Patients and caregivers randomized to the intervention group will continue to receive care in ABC clinical program and IUHP, and have the BCN software installed on either the caregiver's personal mobile device (assuming it meets minimal technical requirements) or a device provided by the study, per participant preference. A research assistant will orient participants to the device, provide training on the BCN software, and troubleshoot technical issues. Participants will receive daytime technical support by phone, electronic support request through a separate app, or printed and in-app help manuals. Hardware, software, and connectivity check-ups will be provided by study research personnel.

The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.

The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary.

Other Names:
  • IUHP Usual Care

BCN is a mobile application (app) for informal caregivers of patients with Alzheimer's Disease and related dementias (ADRD). The BCN app delivers the following behavioral support:

  1. 24/7 psychoeducation and caregiver support on a variety of ADRD related topics, presented as a browse-able library of stories and advice cards or "Notes";
  2. Assessment of informal caregiver status and patients behavioral and psychological symptoms of dementia (BPSD), in the form of the selfadministered HABC Monitor, along with reporting and historical tracking of HABC Monitor scores;
  3. Engagement tools, in particular, (i) a toolkit for saving, sorting, creating/editing, and sharing Notes and (ii) a bi-directional messaging tool for communicating with clinicians or trusted others.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility: Recruitment rate
Time Frame: 15 month accrual period
Recruitment rate will be collected continually and computed at the end of the accrual period by calculating # approached, # agreeing, # consenting, and # consenting / # approached. We will also calculate the monthly rate.
15 month accrual period
Feasibility: Data completeness
Time Frame: 21 month outcome assessment period
Data completion will be collected continually and computed after the final assessment by calculating # complete caregiver burden and BPSD assessments per consenting participant / total possible assessments. We will separately compute missing data and attrition for all causes vs. death in the intervention vs. control groups.
21 month outcome assessment period
Feasibility: BCN usability
Time Frame: 3 months
BCN usability will be assessed in the BCN intervention group at 3 months by a modified System Usability Scale (SUS), a validated 10-item scale (e.g., "Learning to use Brain CareNotes was quick for me") with a 5-point response scale (strongly disagree to strongly agree).
3 months
Feasibility: BCN usability
Time Frame: 6 months
BCN usability will be assessed in the BCN intervention group at 6 months by a modified System Usability Scale (SUS), a validated 10-item scale (e.g., "Learning to use Brain CareNotes was quick for me") with a 5-point response scale (strongly disagree to strongly agree).
6 months
Feasibility: BCN acceptance
Time Frame: 3 months
BCN acceptance will be assessed in the BCN intervention group at 3 months as the mean score on a Behavioral Intention scale (e.g., "If it were up to you, to what extent would you want to use the BCN app?"). The 4-item scale, adapted for health IT, uses a 7-point response scale from 0 (not at all) to 6 (a great deal). Behavioral intention is the canonical assessment for user acceptance of technology.
3 months
Feasibility: BCN acceptance
Time Frame: 6 months
BCN acceptance will be assessed in the BCN intervention group at 6 months as the mean score on a Behavioral Intention scale (e.g., "If it were up to you, to what extent would you want to use the BCN app?"). The 4-item scale, adapted for health IT, uses a 7-point response scale from 0 (not at all) to 6 (a great deal). Behavioral intention is the canonical assessment for user acceptance of technology.
6 months
Feasibility: BCN use
Time Frame: 3 months
BCN use will be collected continually from server activity (via API server queries) for log-in; survey initiation; survey completion; Notes browsed, saved, created, edited; assessment graph used; and message sent and received. We will compute daily and weekly use rates for each use type and for "any" use at 3 months.
3 months
Feasibility: BCN use
Time Frame: 6 months
BCN use will be collected continually from server activity (via API server queries) for log-in; survey initiation; survey completion; Notes browsed, saved, created, edited; assessment graph used; and message sent and received. We will compute daily and weekly use rates for each use type and for "any" use at 6 months.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Caregiver Burden
Time Frame: baseline.
Informal caregiver burden will be assessed by calculating the NPI-Caregiver Distress score (possible range from 0-60) from the researcher administered Neuropsychiatric Inventory (NPI) at baseline.
baseline.
Caregiver Burden
Time Frame: 3 months
Informal caregiver burden will be assessed by calculating the NPI-Caregiver Distress score (possible range from 0-60) from the researcher administered Neuropsychiatric Inventory (NPI) at 3 months.
3 months
Caregiver Burden
Time Frame: 6 months
Informal caregiver burden will be assessed by calculating the NPI-Caregiver Distress score (possible range from 0-60) from the researcher administered Neuropsychiatric Inventory (NPI) at 6 months.
6 months
Patient BPSD severity
Time Frame: baseline
Patient behavioral and psychological symptoms of dementia (BPSD) will be assessed by calculating the NPI total score (possible range from 0-144) from the researcher- administered Neuropsychiatric Inventory (NPI) at baseline.
baseline
Patient BPSD severity
Time Frame: 3 months
Patient behavioral and psychological symptoms of dementia (BPSD) will be assessed by calculating the NPI total score (possible range from 0-144) from the researcher- administered Neuropsychiatric Inventory (NPI) at 3 months.
3 months
Patient BPSD severity
Time Frame: 6 months
Patient behavioral and psychological symptoms of dementia (BPSD) will be assessed by calculating the NPI total score (possible range from 0-144) from the researcher- administered Neuropsychiatric Inventory (NPI) at 6 months.
6 months
Acute care utilization
Time Frame: 3 months
After patient and caregiver have been consented, all-cause hospital and emergency room admissions during the study period will be collected from electronic medical records and the Indiana Network for Patient Care (INPC), the clinical data repository of the regenstrief built regional health information exchange and computed as a rate at 3 months.
3 months
Acute Care Utilization
Time Frame: 6 months
After patient and caregiver have been consented, all-cause hospital and emergency room admissions during the study period will be collected from electronic medical records and the Indiana Network for Patient Care (INPC), the clinical data repository of the regenstrief built regional health information exchange and computed as a rate at 6 months.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Malaz Boustani, MD, MPH, Indiana University
  • Principal Investigator: Richard J. Holden, PhD, Indiana University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 25, 2019

Primary Completion (Actual)

July 31, 2021

Study Completion (Actual)

July 31, 2021

Study Registration Dates

First Submitted

April 12, 2017

First Submitted That Met QC Criteria

April 13, 2017

First Posted (Actual)

April 18, 2017

Study Record Updates

Last Update Posted (Actual)

September 5, 2021

Last Update Submitted That Met QC Criteria

September 1, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data, or results, will be shared through traditional mechanisms such as peer-reviewed journals and presentations at national meetings. The Enhanced Medical Record - Aging Brain Care (eMR-ABC), the dedicated electronic medical record for the Aging Brain Care (ABC) Clinical Program, was developed with the intent of sharing de-identified data with the scientific community. The Indiana Network for Patient Care (INPC) is a state-wide health information exchange. INPC data is collected for patient care purposes and is not "owned" by Indiana University or the Regenstrief Institute, Inc. - each participating health care system or program retains ownership of their data. At present, Indiana University/Regenstrief Institute scientists do not have the direct authority to share even de-identified patient data. Therefore, any request to use these data for research purposes must be adjudicated on a case-by-case basis.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dementia, Alzheimer Type

Clinical Trials on ABC Clinical Program

3
Subscribe